Identification of a Novel Variant in EARS2 Associated with a Severe Clinical Phenotype Expands the Clinical Spectrum of LTBL

Sofia Barbosa-Gouveia, Emiliano González-Vioque, Álvaro Hermida, María Unceta Suarez, María Jesús Martínez-González, Filipa Borges, Liebeth Wintjes, Antonia Kappen, Richard Rodenburg and Maria-Luz Couce

1. Introduction

Mitochondrial diseases are a group of clinically heterogeneous disorders caused by dysfunction of the oxidative phosphorylation (OXPHOS) system and can arise due to defects in genes in the...
nuclear or mitochondrial DNA (nDNA and mtDNA, respectively) [1]. Human mtDNA contains 37 genes encoding 13 subunits of the OXPHOS complexes I, III, IV, and V and two ribosomal RNAs (rRNA) and 22 transfer RNAs (tRNAs) crucial for their translation [2]. The remaining components of mtDNA replication, transcription, and translation processes, including tRNA maturation, initiation and elongation factors, ribosomal proteins, and aminoacyl-tRNA synthetases (mt-aaRSs), are encoded by nDNA, synthesized in the cytosol, and imported into the mitochondria [3,4]. nDNA-encoded mt-aaRS genes produce enzymes that play an important role in protein synthesis by charging tRNAs with their cognate amino acid and ensuring the correct protein translation [5,6]. Pathogenic variants in mt-aaRSs can directly affect the central nervous system (CNS), leading to characteristic brain lesion patterns (e.g., leukodystrophies) that can be identified by magnetic resonance imaging (MRI) [4,7].

The nuclear gene EARS2 (MIM*612799) encodes glutamyl-tRNA synthetase, a member of the class I family of mt-aaRSs. This 523-amino acid protein has an N-terminal mitochondrial targeting signal that enables its importation from the cytoplasm into the mitochondria, where it catalyzes the acylation of tRNAGln with glutamine [8,9]. Genetic defects in EARS2 may lead to combined OXPHOS deficiency (MIM#614924), an autosomal recessive neurologic disorder caused by either compound heterozygous or homozygous variants. Defects in EARS2 have been associated with a specific clinical syndrome called leukoencephalopathy with thalamus and brainstem involvement and high lactate (LTBL) [10].

LTBL has a broad clinical spectrum, ranging from infantile-onset disease (usually after six months of age) with relatively mild neurological symptoms, followed by spontaneous clinical, biochemical, and radiological improvement, to a more severe phenotype with neonatal/early-infantile onset and rapidly progressive CNS disease that stabilizes but does not improve [10–12]. Here, we demonstrate the pathogenicity of EARS2 variants found in compound heterozygosity in a patient with a variation of the classical LTBL phenotype, characterized by infantile-onset, with progression to a severe clinical phenotype and cerebellar atrophy. We discuss the importance of carefully interpreting variant frequency from population databases and of experimental validation using in-vitro analysis for the accurate characterization of disease-causing variants.

2. Materials and Methods

2.1. Study Design

This study was carried out in collaboration with the University Clinical Hospital of Santiago de Compostela (Santiago de Compostela, Spain) and Radboud University Medical Center (Nijmegen, The Netherlands). The patient’s parents provided written informed consent to participation in the study and publication of the results. The relevant clinical information from the medical record was collected for the interpretation of the genetic results. For its execution, this project was submitted for approval by the Autonomous Committee of Ethics of Clinical Research of Galicia (code 2015/410). All experimental protocols were approved by the Radboud University Medical Center and were performed in accordance with relevant guidelines and regulations.

2.2. Clinical Profile

Our female Spanish patient, the first child of healthy nonconsanguineous parents, was born at 42 weeks of gestation after an uneventful pregnancy. Birth weight, length, and head circumference were all within the normal range. Beginning at 12 months of age, the patient presented daily episodes of absence seizures with mild spasticity of the extremities, lateral pulling of the mouth to the right, and sialorrhea. Electroencephalogram readings were initially normal, although results at 19 years old showed irregular and slightly slowed brain activity for her age. Physical examination revealed microcephaly. The patient required assistance to remain seated, which is her best motor performance achieved. Hepatomegaly was absent. Laboratory analyses of blood, urine, and cerebrospinal fluid (CSF) revealed elevated serum and CSF lactate but no alterations in creatine kinase, glucose, liver function, or blood amino acid levels. Brain magnetic resonance imaging (MRI) revealed generalized
leukodystrophy that predominantly affected the thalamus and complete agenesis of the corpus callosum. Assessment of OXPHOS complex enzymatic activity in skeletal muscle at 1 years old revealed a combined deficiency of complexes I and III. Histochemical studies showed normal cytochrome C oxidase (COX) activity, with uniform caliber of the fibers, without structural alterations and no ragged-red fibers. Patient’s mtDNA was sequenced, and the presence of pathogenic variants were discarded. Absence seizures were well-managed at first with empirical phenobarbital treatment. With the appearance of recurrent episodes, carbamazepine was added to the patient’s regimen and was subsequently substituted with vigabatrin. The patient showed progressive intellectual and neurological deterioration and, at 6 years of age, exhibited severe delayed psychomotor development, absence of speech, and spastic tetraparesis. Growth remained poor, with head circumference in the 3rd percentile. Serum lactate levels normalized, and brain MRIs at the ages of 10 and 15 years revealed complete agenesis of the corpus callosum, severe atrophy of the cerebral white matter, and diffuse cerebellar atrophy. By 17 years of age, complete seizure control had not been achieved, and levetiracetam treatment was initiated in parallel with vigabatrin treatment. At follow-up at 19 years, the patient was experiencing 2 seizures episodes per month and was slightly more alert and responsive, although absence of speech and spastic tetraparesis persisted.

2.3. Targeted Next-Generation Sequencing

DNA was isolated from the patient’s lymphocytes and analyzed with targeted next-generation sequencing (NGS) panels for mitochondrial diseases. In our unit, we have designed a multi-gene panel consisting of 150 nuclear genes coding for respiratory chain complex subunits and proteins previously implicated in OXPHOS function.

Genetic data were analyzed by NGS technology through a process consisting of enrichment with an in-solution hybridization technology (Sure Select XT; Agilent Technologies, Santa Clara, CA, USA), followed by subsequent sequencing on a Miseq platform (Illumina, San Diego, CA, USA). A custom Sure Select probe library was designed to capture the exons and exon-intron boundaries of the targeted genes [13]. Sequence capture, enrichment, and elution were performed in accordance with the manufacturer’s instructions. Image analysis and processing of the sequence fluorescence intensity (“base calling”) was performed with Real Time Analysis (RTA) software v.1.8.70 (Illumina), and the FastQC v0.10.1 program was used for data quality control. Reads were aligned to the reference genome GRCh37 using BWA v0.7.9a [14]. NGSrich v0.7.5 software [15] was used as a control prior to variant detection and BEDTools 2.17.0 [16] and Picard 1.114 [17] for intermediate steps. VarScan v.2.3.6 [18] and SAMtools v0.1.19 [19] were used for variant detection for indels and Single Nucleotide Polymorphism (SNPs), respectively, and ANNOVAR for variant annotation [20].

To ensure reliable clinical interpretation of the detected variants, prioritization criteria were applied to predict their pathogenicity in accordance with the ACMG assay mix containing 0.3-mM acetyl-CoA guidelines [21].

2.4. Cell Culture

Patient fibroblasts from skin biopsy performed at 19 years old and a control fibroblast line routinely used for research purposes were cultured in M199 medium (Gibco, Thermo Fisher Scientific, Waltham, MA, USA) supplemented with 10% v/v fetal calf serum (FCS) and 1% v/v penicillin/streptomycin (Gibco) at 37 °C and 5% CO₂.

2.5. Mitochondrial Isolation

Pelleted fibroblasts from the patient and from the control cell line were resuspended in ice-cold Tris-HCl (10 mM, pH 7.6). Cells were then disrupted in a Potter-Elvehjem homogenizer at 1800 rpm, and sucrose (250 mM) was added to make the samples isotonic. The homogenized cell samples were then centrifuged for 10 min at 600× g, and the mitochondria pellet was obtained after centrifugation of the supernatant for 10 min at 14,000× g.
2.6. Respirometry and Measurement of OXPHOS Activity

A Seahorse XFe96 Extracellular Flux analyzer (Seahorse Bioscience, Agilent) was used to measure the oxygen consumption rate (OCR). On the day before the assay, control and patient fibroblasts were seeded at 10,000 cells per well in cell culture medium (M199 supplemented with 10% FCS and 1% pen/strep) and incubated overnight at 37 °C and 5% CO2. On the day of the assay, cell culture medium was replaced with Agilent Seahorse XP Base Medium with 10-mM glucose (Sigma Aldrich, St. Louis, MO, USA), 1-mM sodium pyruvate (Gibco), and 200-mM l-glutamine (Life Sciences Group, Barnet, UK) and then incubated for 1 h at 37 °C without CO2. Baseline cellular OCR was measured 8 times, followed by 4 measurement cycles after addition of the following inhibitors: 1-µM oligomycin A (Sigma), 2.0-µM and 4.0-µM carbonyl cyanide 4-(trifluoromethoxy) phenylhydrazone (FCCP) (Sigma), and 0.5-µM rotenone and 0.5-µM antimycin A (Sigma). After OCR measurements, the cell medium was removed and replaced with 0.33% Triton X-100, and 10-mM Tris-HCl (pH 7.6). Seahorse plates were stored at −80 °C and thawed afterwards. Citrate synthase activity was measured spectrophotometrically, at 37 °C, using a Tecan Spark spectrophotometer. The assay mix contained 0.3-mM acetyl-CoA, 0.1-mM dithionitrobenzoic acid (DTNB), 0.025% Triton X-100, and 10-mM Tris-HCl, pH 8.1. Measurements were based on the absorption at 412 nm of thionitrobenzoic acid (TNB), and citrate synthase activity was calculated based on the rate of dithionitrobenzoic acid (DTNB) conversion in the presence of oxaloacetate. OCR was measured before and after the addition of inhibitors and was normalized to the activity of the citrate synthase (CS) [22] to avoid the effect of differences in the mitochondrial content or cell number.

The enzymatic activities of complexes I–V were assayed spectrophotometrically using mitochondrial extracts prepared as previously described in mitochondrial isolation. These measurements were performed according to the current protocols in use in the Nijmegen Center for Mitochondrial Disorders [23]. All assays were performed in duplicate using a Konelab 20XT auto-analyzer (Thermo Fischer Scientific).

3. Results

3.1. Molecular Genetics and In-Silico Analysis of EARS2 Variants

NGS analysis enabled the identification of two compound heterozygous variants in EARS2 (NM_001083614.1) in our patient (Figure 1): variant c.670G>A (p.Gly224Ser) has been previously described in a patient with mild LTBL [10], while c.376C>T (p.Gln126*) has not to date been included in any human genetic variation database.

The identified EARS2 variants were analyzed in silico to determine the degree of evolutionary conservation, predicted pathogenicity, functional consequences, and minor allele frequency (MAF) within the population (Table S1, Supplementary Materials). According to GERP [24], PhyloP [25], and phastCons [25], both variants are located in areas of the EARS2 protein that are highly conserved through evolution. The pathogenicity was predicted using MutationTaster [26] (prediction and disease-causing) and by calculating the FATHMM [27] and DANN [28] scores, which corresponded to “damaging”. The missense variant c.670G>A is located in exon 4 and causes an amino acid change from a nonpolar glycine to an uncharged polar serine at residue 224. Both SIFT [29] and Provean [30] software predicted a damaging effect of this variant on the protein function. The nonsense variant c.376C>T, located in exon 3, was predicted to be disease-causing and damaging by MutationTaster and FATHMM, respectively.

Segregation studies were performed by Sanger sequencing to determine the inheritance pattern of the identified variants (Figure 1). The missense variant was inherited from the patient’s mother and the nonsense variant from the father.
3.2. Mitochondrial Respiration and OXPHOS Activity

Measurement of the OCR and extracellular acidification rate (ECAR), normalized by the mitochondrial content, revealed decreases in both the OCR and the OCR/ECAR ratio in the patient’s fibroblasts, indicating a reduced electron flow through the respiratory chain (Figure 2A,B). These findings reflect a general deficiency in the cumulative proficiency of the entire set of mitochondrial respiratory chain complexes in the patient’s fibroblasts.

Figure 1. Reverse sequence chromatograms showing the results of Sanger sequencing. (A) The missense variant c.670G>A (p.Gly224Ser), located in exon 4, was inherited from the patient’s mother and the nonsense variant c.376C>T (p.Gln126*), located in exon3, from the father. The patient harbored both variants in EARS2 in compound heterozygosity. (B) Schematic showing EARS2 domains in which all variants identified to date in leukoencephalopathy with thalamus and brainstem involvement and high lactate (LTBL) patients are highlighted.

Figure 2. (A) Oxygen consumption rate (OCR) measured before and after the addition of inhibitors. The Seahorse XF Cell Mito Stress Test uses compounds of respiration that target components of the electron transport chain (ETC) in the mitochondria to reveal key parameters of the metabolic functions. These modulators are ETC inhibitors (oligomycin, carbonyl cyanide 4-(trifluoromethoxy) phenylhydrazone (FCCP), and a mixture of rotenone and antimycin A), which are serially injected to measure the ATP production, maximal respiration (Max Resp), nonmitochondrial respiration (Non-Mito Resp), proton leak, spare respiratory capacity (SRC), and basal respiration (Basal Resp). (B) The basal energy metabolism of each cell line was assessed by analyzing the OCR/extracellular acidification rate (ECAR) ratios following the sequential injection of the inhibitors. (C) Measurements of the enzyme activities for the different oxidative phosphorylation (OXPHOS) complexes in the patient’s fibroblasts (reference range deemed in a healthy population). CS, citrate synthase.
The spectrophotometric analysis of respiratory chain enzyme activity revealed a slight deficiency in complex III in the patient’s fibroblasts and normal levels of activity of complexes I, II, IV, and V (Figure 2C). Additionally, mitochondrial mass differences were detected between the patient and control—160 U/L and 339 U/L, respectively—regarding the CS measurement.

4. Discussion

LTBL is a condition with a well-defined clinical phenotype, characterized by extensive symmetrical deep white matter abnormalities and signal changes in the thalami and brainstem, along with lactic acidosis [10,31]. Two distinct clinical courses are described: severe and moderate. The severe form is characterized by early-onset, delayed psychomotor development, seizures, hypotonia, and persistently elevated lactate levels, with progressive atrophy of the affected brain structures. The mild form usually manifests clinically after six months of age with irritability and psychomotor regression, although patients can show clinical and biochemical improvements. The occurrence and extent of recovery most likely depends on the severity of brain damage caused by the first symptomatic episode; some children with the most severe phenotype can die after the first clinical event [31–34]. Less common findings reported in LTBL include anemia, tubulopathy, hepatopathy, absence of the thalami, and even the absence of characteristic neuroimaging findings [10,35–37]. The clinical course of our patient does not appear to correspond to either of the two clinical courses described: she has a severe clinical presentation that initially manifested at 12 months of age, characterized by absence seizures with mild spasticity of the extremities. In addition to the typical clinical features of LTBL, MRIs at 10 (Figure 3A) and 15 (Figure 3B) years of age revealed diffuse atrophy of the cerebellum that was not present in the early stages of the disease. Later-onset of cerebellar atrophy was also identified in a patient reported by Steenweg et al. (Table S2, Supplementary Materials). In addition to the cerebellar atrophy associated with LTBL (Table S2, Supplementary Materials), our patient exhibited progressive brain lesions with no signs of improvement, which is commonly reported in cases diagnosed after four months of age [10,36,38,39]. It has been difficult to establish a correlation between patients’ genotypic and phenotypic characteristics, since the same variant may be associated with different clinical signs, even among members of the same family [10,39].

![Figure 3](image-url)

**Figure 3.** MRI images of our patient acquired at 10 (A) and 15 (B) years of age, showing complete agenesis of the corpus callosum (indicated with a red star) and cerebellar atrophy (indicated with white arrows). Note also the dilation of the fourth ventricle and enlargement of the interfolial spaces within a normal-sized posterior fossa.

The evaluation of all LTBL cases with homozygous or compound heterozygous variants in EARS2 reported to date indicates that certain aspects of the established LTBL phenotype do not appear in all cases of this pathology. As shown in Table S2 of the Supplementary Materials, leukoencephalopathy
Genes 2020, 11, 1028

was absent in patients 14 and 26, the thalamus and brainstem involvement was absent in patients 18 and 29, and lactic acidosis was absent in patient 18 (clinical conditions that do not correspond to the classical LTBL phenotype are shown in bold).

The data presented here support the pathogenicity of the compound heterozygous EARS2 variants detected in our patient. We provide the first description of the nonsense variant c.376C>T (p.Gln126*), inherited from the patient’s father. Our patient also carried the variant c.670G>A (p.Gly224Ser), which was previously identified in a patient (patient 7, Table S2) with mild LTBL by Steenweg et al. [10]. Although this variant has a high frequency in allele-population databases such as gnomAd and ExAC (0.00087 and 0.00119, respectively), especially in African populations, a software in-silico analysis predicted a high level of pathogenicity for this variant. The combination of severe changes, like nonsense with milder missense variants, is a common molecular mechanism in EARS2-associated diseases.

Mitochondrial function characterization using the patient’s fibroblasts revealed a mitochondrial dysfunction due to abnormal mitochondrial respiration, as evidenced by a decrease in the OCR/ECAR ratio. The decrease in OCR and the increase in lactate production observed in our patient are likely the consequences of deficient respiration due to general impairment of the entire set of mitochondrial respiratory chain complexes. The analysis of respiratory chain enzymatic activity in muscle samples from our patient revealed deficiencies in complexes I and III. However, the same analysis of fibroblast samples only showed a mild decrease in complex III activity. Despite our patient’s severe clinical presentation and the clear deficit in fibroblast mitochondrial function, these discrepancies between muscle and fibroblast findings are not uncommon in nuclear-encoded gene-associated disorders [23]. Importantly, the various ARS2 gene defects are notoriously variable when it comes to issue-specific biochemical phenotypes [40].

Our findings highlight the complexity of OXPHOS enzymes. On the one hand, we have a system composed of multi-subunit enzymes encoded both by mtDNA and nDNA (except for complex II, which is only encoded by nDNA). Consequently, pathogenic variants in both genomes can lead to the highly heterogeneous clinical presentations characteristics of mitochondrial disorders. On the other hand, this tight relationship guarantees a close coevolution of the two genomes. Therefore, any inconsistency affecting either genome may have severe negative effects on the cellular fitness [41]. In fact, studies of Drosophila melanogaster have shown that interactions between nDNA-encoded mt-aaRSs and mitochondrial tRNAs may not only delay development and fecundity but, also, affect the activities of oxidative phosphorylation complexes I, III, and IV, suggesting that these interactions may be targets of compensatory molecular evolution [42]. Several features of mtDNA, including a high mutation rate and uniparental inheritance, makes mtDNA more likely to accumulate mutations in the population. These changes, in turn, could drive adaptations in nDNA, given the intimate interactions between both genomes. In different populations, this coevolution is driven by different factors and in different directions [41,43], leading to distinct consequences of nDNA-encoded variants, depending on the mtDNA background. This could explain why variant c.670G>A (p.Gly224Ser), which was detected in our patient and in the LTBL case described by Steenweg et al., is predicted as pathogenic and associated with LTBL disease despite being classified as benign, owing to its high frequency in African populations. This hypothesis underscores the need for caution when consulting population frequency databases, particularly when studying variants in nuclear genes that interact directly with mitochondrial genes.

Taken together, the results of the functional analyses and family studies presented here enabled the correct identification of the pathogenicity of the variants identified in our patient, thereby expanding the clinical spectrum of LTBL to include cerebellar atrophy. Establishing the pathogenicity has significant implications for the diagnosis and management of these disorders. However, the relationship between EARS2 variants and the phenotypic characteristics of LTBL remain poorly understood, and further studies are needed to elucidate the molecular mechanisms underlying this disease.
Supplementary Materials: The following are available online at http://www.mdpi.com/2073-4425/11/9/1028/s1, Table S1: In silico analysis to predict EARS2 variant pathogenicity according to AMCG guidelines, Table S2: Clinical features in the patients reported so far harboring pathogenic variants in EARS2, Table S3: Genes included in the mitochondrial gene panel. References [44–47] are cited in the Supplementary Materials.

Author Contributions: Conceptualization, S.B.-G., R.R., and M.-L.C.; methodology, L.W. and A.K.; software, L.W. and A.K.; validation, Á.H., M.U.S., M.J.M.-G., E.G.-V., F.B., R.R., and M.-L.C.; formal analysis S.B.-G., R.R., and M.-L.C.; investigation, S.B.-G., F.B., Á.H., E.G.-V., M.U.S. and M.J.M.-G.; resources, L.W., Á.H., M.U.S., M.J.M.-G., E.G.-V., and F.B.; data curation, S.B.-G., R.R., and M.-L.C.; writing—original draft preparation, S.B.-G., R.R., and M.-L.C.; writing—review and editing, S.B.-G., R.R., and M.-L.C.; visualization, Á.H., E.G.-V., M.U.S. and M.J.M.-G.; supervision, R.R. and M.-L.C.; project administration, S.B.-G.; and funding acquisition, S.B.-G. All authors have read and agreed to the published version of the manuscript.

Funding: This study was supported with a competitive PhD grant from a pre-Doctoral scholarship for research groups of the Health Research Institute of Santiago (IDIS).

Acknowledgments: We are extremely grateful to the family for their collaborative support in this work. We also want to thank Frans van den Brandt and Daan Panneman for their help.

Conflicts of Interest: The authors declare no conflict of interest.

References

1. Gorman, G.S.; Chinnery, P.F.; DiMauro, S.; Hirano, M.; Koga, Y.; McFarland, R.; Suomalainen, A.; Thorburn, D.R.; Zeviani, M.; Turnbull, D.M. Mitochondrial diseases. Nat. Rev. Dis. Primers 2016, 2, 16080. [CrossRef] [PubMed]
2. Kotrys, A.V.; Szczesny, R.J. Mitochondrial Gene Expression and Beyond—Novel Aspects of Cellular Physiology. Cells 2019, 9, 17. [CrossRef] [PubMed]
3. Christian, B.E.; Spremulli, L.L. Mechanism of Protein Biosynthesis in Mammalian Mitochondria. Biochim. Biophys. Acta 2012, 1819, 1035–1054. [CrossRef] [PubMed]
4. González-Serrano, L.E.; Chihade, J.W.; Sissler, M. When a common biological role does not imply common disease outcomes: Disparate pathology linked to human mitochondrial aminoacyl-tRNA synthetases. J. Biol. Chem. 2019, 294, 5309–5320. [CrossRef] [PubMed]
5. Meyer-Schuman, R.; Antonellis, A. Emerging mechanisms of aminoacyl-tRNA synthetase mutations in recessive and dominant human disease. Hum. Mol. Genet. 2017, 26, R114–R127. [CrossRef]
6. Ogreniović, J.; Simonović, M. Human aminoacyl-tRNA synthetases in diseases of the nervous system. RNA Biol. 2017, 15, 623–634. [CrossRef]
7. Sissler, M.; González-Serrano, L.E.; Westhof, E. Recent Advances in Mitochondrial Aminoacyl-tRNA Synthetases and Disease. Trends Mol. Med. 2017, 23, 693–708. [CrossRef]
8. Bonnefond, L.; Fender, A.; Rudinger-Thirion, J.; Giegé, R.; Florentz, C.; Sissler, M. Toward the full set of human mitochondrial aminoacyl-tRNA synthetases characterization of AspRS and TyrRS. Biochemistry 2005, 44, 4805–4816. [CrossRef]
9. Schmidt, O.; Pfanner, N.; Meisinger, C. Mitochondrial protein import: From proteomics to functional mechanisms. Nat. Rev. Mol. Cell Biol. 2010, 11, 655–667. [CrossRef]
10. Steenweg, M.E.; Ghezzi, D.; Haack, T.; Abbink, T.E.M.; Martinelli, D.; van Berkel, C.G.M.; Bley, A.; Diogo, L.; Grillo, E.; Te Water Naudé, J.; et al. Leukoencephalopathy with thalamus and brainstem involvement and high lactate “LTBL” caused by EARS2 mutations. Brain 2012, 135, 1387–1394. [CrossRef]
11. Diodato, D.; Ghezzi, D.; Tiranti, V. The Mitochondrial Aminoacyl tRNA Synthetases: Genes and Syndromes. Int. J. Cell Biol. 2014, 2014, 7517-24. [CrossRef] [PubMed]
12. Biancheri, R.; Lamantea, E.; Severino, M.; Diodato, D.; Pedemonte, M.; Cassandrini, D.; Ploenderl, A.; Trucco, F.; Fiorillo, C.; Minetti, C.; et al. Expanding the Clinical and Magnetic Resonance Spectrum of Leukoencephalopathy with Thalamus and Brainstem Involvement and High Lactate (LTBL) in a Patient Harboring a Novel EARS2 Mutation. JIMD Rep. 2015, 23, 85–89. [CrossRef] [PubMed]
13. Agilent SureDesign. Available online: https://earray.chem.agilent.com/suredesign/ (accessed on 11 October 2018).
14. Li, H.; Durbin, R. Fast and accurate short read alignment with Burrows-Wheeler transform. Bioinformatics 2009, 25, 1754–1760. [CrossRef] [PubMed]
15. NGSrich. Available online: https://sourceforge.net/projects/ngsrich/ (accessed on 11 October 2018).
16. Quinlan, A.R.; Hall, I.M. BEDTools: A flexible suite of utilities for comparing genomic features. Bioinformatics 2010, 26, 841–842. [CrossRef]

17. Picard Tools—By Broad Institute. Available online: http://broadinstitute.github.io/picard/ (accessed on 15 March 2019).

18. Koboldt, D.C.; Chen, K.; Wylie, T.; Larson, D.E.; McLellan, M.D.; Mardis, E.R.; Weinstock, G.M.; Wilson, R.K.; Ding, L. VarScan: Variant detection in massively parallel sequencing of individual and pooled samples. Bioinformatics 2009, 25, 2283–2285. [CrossRef]

19. Li, H.; Handsaker, B.; Wysoker, A.; Fennell, T.; Ruan, J.; Homer, N.; Marth, G.; Abecasis, G.; Durbin, R. 1000 Genome Project Data Processing Subgroup the Sequence Alignment/Map format and SAMtools. Bioinformatics 2009, 25, 2078–2079. [CrossRef]

20. Wang, K.; Li, M.; Hakonarson, H. ANNOVAR: Functional annotation of genetic variants from high-throughput sequencing data. Nucleic Acids Res. 2010, 38, e164. [CrossRef]

21. Richards, S.; Aziz, N.; Bale, S.; Bick, D.; Das, S.; Gastier-Foster, J.; Grody, W.W.; Lyon, E.; Spector, E.; et al. Standards and guidelines for the interpretation of sequence variants: A joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology. Genet. Med. 2015, 17, 405–424. [CrossRef]

22. Srere, P. [1] Citrate synthase. [EC 4.1.3.7. Citrate oxaloacetate-lyase (CoA-acetylating)]. Methods 1969, 13, 3–11. [CrossRef]

23. Rodenburg, R.J.T. Biochemical diagnosis of mitochondrial disorders. J. Inherit. Metab. Dis. 2011, 34, 283–292. [CrossRef]

24. Cooper, G.M.; Goode, D.L.; Ng, S.B.; Sidow, A.; Bamshad, M.J.; Shendure, J.; Nickerson, D.A. Single-nucleotide evolutionary constraint scores highlight disease-causing mutations. Nat. Methods 2010, 7, 250–251. [CrossRef] [PubMed]

25. Ramani, R.; Krumholz, C.; Huang, Y.-F.; Siepel, A. PhastWeb: A web interface for evolutionary conservation scoring of multiple sequence alignments using phastCons and phyloP. Bioinformatics 2019, 35, 2320–2322. [CrossRef] [PubMed]

26. Schwarz, J.M.; Rödelsperger, C.; Schuelke, M.; Seelow, D. MutationTaster evaluates disease-causing potential of sequence alterations. Nat. Methods 2010, 7, 575–576. [CrossRef] [PubMed]

27. Rogers, M.F.; Shihab, H.A.; Mort, M.; Cooper, D.N.; Gaunt, T.R.; Campbell, C. FATHMM-XF: Accurate prediction of pathogenic point mutations via extended features. Bioinformatics 2018, 34, 511–513. [CrossRef] [PubMed]

28. Talim, B.; Pyle, A.; Griffith, B.; Topaloglu, H.; Tokatli, A.; Keogh, M.J.; Santibanez-Koref, M.; Chinnery, P.F.; Horvath, R. Multisystem fatal infantile disease caused by a novel homozygous EARS2 mutation. Brain 2013, 136, e228. [CrossRef] [PubMed]

29. Sellars, E.A.; Balmakund, T.; Bosanko, K.; Nichols, B.L.; Kahler, S.G.; Zarate, Y.A. Severe Metabolic Acidosis and Hepatopathy due to Leukoencephalopathy with Thalamus and Brainstem Involvement and High Lactate. Neuropediatrics 2017, 48, 108–110. [CrossRef] [PubMed]
36. Kevelam, S.H.; Klouwer, F.C.C.; Fock, J.M.; Salomons, G.S.; Bugiani, M.; van der Knaap, M.S. Absent Thalami Caused by a Homozygous EARS2 Mutation: Expanding Disease Spectrum of LTBL. *Neuropediatrics* 2016, 47, 64–67. [CrossRef] [PubMed]

37. Prasun, P.; Mintz, C.; Cork, E.; Naidich, T.P.; Webb, B.D. Broad spectrum of clinical presentation in EARS2 beyond typical “leukoencephalopathy with thalamus and brain stem involvement”. *J. Neurol. Sci.* 2019, 406, 116448. [CrossRef]

38. Güngör, O.; Özkaya, A.K.; Şahin, Y.; Güngör, G.; Dilber, C.; Aydin, K. A compound heterozygous EARS2 mutation associated with mild leukoencephalopathy with thalamus and brainstem involvement and high lactate (LTBL). *Brain Dev.* 2016, 38, 857–861. [CrossRef]

39. Şahin, S.; Cansu, A.; Kalay, E.; Dinçer, T.; Kul, S.; Çağrı, İ.M.; Kamaşak, T.; Budak, G.Y. Leukoencephalopathy with thalamus and brainstem involvement and high lactate caused by novel mutations in the EARS2 gene in two siblings. *J. Neurol. Sci.* 2016, 365, 54–58. [CrossRef]

40. Kuo, M.E.; Antonellis, A. Ubiquitously Expressed Proteins and Restricted Phenotypes: Exploring Cell-Specific Sensitivities to Impaired tRNA Charging. *Trends Genet.* 2020, 36, 105–117. [CrossRef]

41. Chou, J.-Y.; Leu, J.-Y. The Red Queen in mitochondria: Cyto-nuclear co-evolution, hybrid breakdown and human disease. *Front. Genet.* 2015, 6. [CrossRef]

42. Meiklejohn, C.D.; Holmbeck, M.A.; Siddiq, M.A.; Abt, D.N.; Rand, D.M.; Montooth, K.L. An Incompatibility between a mitochondrial tRNA and its nuclear-encoded tRNA synthetase compromises development and fitness in Drosophila. *PLoS Genet.* 2013, 9, e1003238. [CrossRef]

43. Havird, J.C.; Sloan, D.B. The Roles of Mutation, Selection, and Expression in Determining Relative Rates of Evolution in Mitochondrial versus Nuclear Genomes. *Mol. Biol. Evol.* 2016, 33, 3042–3053. [CrossRef]

44. Kohda, M.; Tokuzawa, Y.; Kishita, Y.; Nyuzuki, H.; Moriyama, Y.; Mizuno, Y.; Hirata, T.; Yatsuka, Y.; Yamashita-Sugahara, Y.; Nakachi, Y.; et al. A Comprehensive Genomic Analysis Reveals the Genetic Landscape of Mitochondrial Respiratory Chain Complex Deficiencies. *PLoS Genet.* 2016, 12, e1005679. [CrossRef]

45. Taskin, B.D.; Karalok, Z.S.; Gurkas, E.; Aydin, K.; Aydogmus, U.; Ceylaner, S.; Karaer, K.; Yilmaz, C.; Pearl, P.L. Early-Onset Mild Type Leukoencephalopathy Caused by a Homozygous EARS2 Mutation. *J. Child Neurol.* 2016, 31, 938–941. [CrossRef] [PubMed]

46. Pronicka, E.; Piekutowska-Abramczuk, D.; Ciara, E.; Trubicka, J.; Rokicki, D.; Karkucińska-Więckowska, A.; Pajdowska, M.; Jurkiewicz, E.; Halat, P.; Kosińska, J.; et al. New perspective in diagnostics of mitochondrial disorders: Two years’ experience with whole-exome sequencing at a national paediatric centre. *J. Transl. Med.* 2016, 14. [CrossRef] [PubMed]

47. Balushi, A.A.; Matviychuk, D.; Jobling, R.; Salomons, G.S.; Blaser, S.; Mercimek-Andrews, S. Phenotypes and genotypes of mitochondrial aminoacyl-tRNA synthetase deficiencies from a single neurometabolic clinic. *JIMD Rep.* 2020, 51, 3–10. [CrossRef] [PubMed]

© 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).